drugset / Trial / NCT02702739

Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly HCV Cirrhotic Patients

NCT02702739

Phase 4 Completed 270 enrolled Azienda Ospedaliera San Camillo Forlanini
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The proportion of HCV infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real world efficacy and safety of the combination of Sofosbuvir and Simeprevir (SOF/SMV) plus a flat dose of ribavirin (RBV) in elderly patients compared to younger patients.

Timeline

Start
2015-01
Primary completion
2015-12
Completion
2016-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ribavirin Small molecule 800 mg
Comparator Simeprevir Small molecule 150 mg
Comparator Sofosbuvir Small molecule 400 mg

Indications